Company intelligence / Profile preview
Onena Medicines
Allschwil, Switzerlandonenameds.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Onena's drugs neutralize a novel class of secreted growth factors called Dual SMAD Inhibiting Proteins (DSIPs). Cancer cells rely on DSIP activity to program themselves to grow by ignoring environmental physiological controls. Blocking DSIPs, as demonstrated in vivo by Onena, elicits cancer cell reprogramming, resulting in apoptosis.
- Therapeutic areas
- OncologyEndocrinologyRare DiseasesHematology
- Modalities
- AntibodiesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Crown BioscienceCancer Research Center LyonHAWK Biosystems
Beyond the preview
Go deeper on Onena Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Onena Medicines.